Kamada Investor Relations Material

Kamada Ltd. is a globall biopharmaceutical company that focuses on the development, production, and marketing of plasma-derived protein therapeutics. The company is known for its specialty in products designed for rare diseases, operating across two main segments: Proprietary Products and Distribution. Kamada's diverse product range includes treatments for conditions such as immune thrombocytopenic purpura, hepatitis B, varicella, and Alpha-1 Antitrypsin Deficiency (AATD), among others. Additionally, it has developed specific immunoglobulins for various applications, including rabies and diseases caused by Rh-negative in the fetus. Kamada markets its products through strategic partnerships and distributors internationally, including collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. The company prides itself on its industry-leading manufacturing capabilities and a robust development pipeline aimed at addressing unmet medical needs. Kamada Ltd. is headquartered in Rehovot, Israel, and its shares are listed on the Nasdaq.